Referencia número: HY-B0504

Creatinine

(Synonyms: NSC13123)

6 Cited Publications

Revisión del cliente

Based on 6 publication(s) in Google Scholar

Creatinine (NSC13123) is an orally active, blood-brain barrier-permeable modulator of GABAA and NMDA receptors, with activities of antioxidation and metabolic regulation. Creatinine is generated via non-enzymatic conversion of creatine and phosphocreatine in muscle. Creatinine serum levels correlate with muscle mass, glomerular filtration rate, and extrarenal clearance, serving as an evaluation biomarker for renal function, muscle mass, and clinical outcomes, and used for perioperative renal risk assessment. In addition, Creatinine can induce specific Cryptococcus species to produce creatinine deiminase and act as their nitrogen source, while it can be secreted via renal tubules. Creatinine is widely used in research related to various diseases such as neurodegenerative diseases, psychiatric disorders, acute kidney injury, chronic kidney disease, and renal failure.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 99.92%
No. CAS: 60-27-5
Fòrmula: C₄H₇N₃O
Peso molecular:113.12

Almacenamiento:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Creatinine Chemical Structure

No. CAS: 60-27-5

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- In Vitro
- In Vivo
- Ensayo clínico
Chemical Information
Publications (6)
Solvente y solubilidad
- In Vitro
- In Vivo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

IC₅₀ & Target

Microbial Metabolite

Human Endogenous Metabolite

NMDA Receptor

Ver todos los productos específicos de isoformas Endogenous Metabolite :

Ver todos los productos específicos de isoformas iGluR :

In Vitro

Creatinine (20-180 μM; 24 h) induces a hypermetabolic state in primary inguinal and epididymal adipocytes by activating the futile creatine cycle. 20 μM Creatinine activates inguinal adipocytes, while 180 μM Creatinine activates both inguinal and epididymal adipocytes^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Creatinine (0.1 g/kg; i.p.; daily; 7 d) exacerbates adipose tissue wasting in mice with Unilateral Ureteral Obstruction (UUO)- or renal Ischemia-Reperfusion Injury (IRI)-induced chronic kidney disease (CKD) by increasing creatine accumulation and activating pathways associated with the futile creatine cycle^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 wild type mouse with Chronic kidney disease (male, 8 weeks old, unilateral ureteral obstruction model)^[1]
Dosage:

0.1 g/kg
Administration:

i.p.; daily; 7 days
Result:

Enhanced loss of inguinal (subcutaneous) and epididymal (visceral) adipose tissues relative to UUO-only mice; increased creatine levels in both subcutaneous and visceral adipose tissues; increased the proportion of multilocular adipocytes in both subcutaneous and visceral adipose tissues; upregulated expression of Prdm16, Pgc1α, CKB, Alpl, and Cox7a genes in subcutaneous and visceral adipose tissues

Ensayo clínico

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

No. CAS 60-27-5
Appearance Solid
Peso molecular 113.12
Fòrmula C₄H₇N₃O
Color White to off-white
SMILES

O=C1N=C(N)N(C)C1
Synonyms

NSC13123
Structure Classification
- Others
Initial Source
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (6)

All

Sort by:

Journal Impact Factor

Nature

Lithocholic acid phenocopies anti-ageing effects of calorie restriction. [Abstract]

2025 Jul;643(8070):192-200. PMID: 39695227
Biomed Pharmacother

Pharmacokinetic profiling of ZCL-278, a cdc42 inhibitor, and its effectiveness against chronic kidney disease. [Abstract]

2024 Aug 23:179:117329. PMID: 39180793
Emerg Contam

2024 Dec, 10, 4, 100351.
Appl Surf Sci

2018 Nov 1, 457:684-694.
J Chromatogr B Analyt Technol Biomed Life Sci

Simultaneous determination of choline, L-carnitine, betaine, trimethylamine, trimethylamine N-oxide, and creatinine in plasma, liver, and feces of hyperlipidemic rats by UHPLC-MS/MS. [Abstract]

2024 Jun 25:1243:124210. PMID: 38936270
Research Square Preprint

2021 Aug.

Solvente y solubilidad

In Vitro:

H₂O : 33.33 mg/mL (294.64 mM; Need ultrasonic)

DMSO : 2.5 mg/mL (22.10 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

8.8402 mL

44.2008 mL

88.4017 mL

5 mM

1.7680 mL

8.8402 mL

17.6803 mL

10 mM

0.8840 mL

4.4201 mL

8.8402 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 33.33 mg/mL (294.64 mM); Clear solution; Need ultrasonic

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (275 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Fang J, et al. Creatinine promotes adipose tissue wasting in chronic kidney disease via creatine and futile creatine cycle. Mol Metab. 2025;98:102191. [Content Brief]

[2]. Allen PJ, et al. Creatine metabolism and psychiatric disorders: Does creatine supplementation have therapeutic value?. Neurosci Biobehav Rev. 2012;36(5):1442-1462. [Content Brief]

[3]. Polacheck I, et al. Creatinine metabolism in Cryptococcus neoformans and Cryptococcus bacillisporus. J Bacteriol. 1980;142(1):15-20. [Content Brief]

[4]. Zhang H, et al. Boron nitride/gold nanocomposites for crystal violet and creatinine detection by surface-enhanced Raman spectroscopy[J]. Applied Surface Science, 2018, 457: 684-694.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / H₂O	1 mM	8.8402 mL	44.2008 mL	88.4017 mL	221.0042 mL
	5 mM	1.7680 mL	8.8402 mL	17.6803 mL	44.2008 mL
	10 mM	0.8840 mL	4.4201 mL	8.8402 mL	22.1004 mL
	15 mM	0.5893 mL	2.9467 mL	5.8934 mL	14.7336 mL
	20 mM	0.4420 mL	2.2100 mL	4.4201 mL	11.0502 mL
H₂O	25 mM	0.3536 mL	1.7680 mL	3.5361 mL	8.8402 mL
	30 mM	0.2947 mL	1.4734 mL	2.9467 mL	7.3668 mL
	40 mM	0.2210 mL	1.1050 mL	2.2100 mL	5.5251 mL
	50 mM	0.1768 mL	0.8840 mL	1.7680 mL	4.4201 mL
	60 mM	0.1473 mL	0.7367 mL	1.4734 mL	3.6834 mL
	80 mM	0.1105 mL	0.5525 mL	1.1050 mL	2.7626 mL
	100 mM	0.0884 mL	0.4420 mL	0.8840 mL	2.2100 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Creatinine

6 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

Creatinine

Anti-Infection Compound Library

Membrane Transporter/Ion Channel Compound Library

Metabolism/Protease Compound Library

Neuronal Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Clinical Compound Library

CNS-Penetrant Compound Library

Human Endogenous Metabolite Compound Library

Drug Repurposing Compound Library

Anti-COVID-19 Compound Library

Orally Active Compound Library

Neurotransmitter Receptor Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Alzheimer's Disease Compound Library

Gut Microbial Metabolite Library

Microbial Metabolite Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Food-Sourced Compound Library

Inactive Ingredient Library

Rare Diseases Drug Library

Anti-Cancer Natural Product Library

GABA Receptor Compound Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Animal-Sourced Natural Product Library

Ion Channel Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Endogenous Metabolite Library

Mass Spectrometry Human Metabolite Library

Mouse Metabolite Compound Library

Cosmetic Ingredient Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Amino Acid Metabolite Compound Library

Chinese Baijiu Compound Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Creatinine

Ver todos los productos específicos de isoformas Endogenous Metabolite

Ver todos los productos específicos de isoformas iGluR

Actividad biológica

Chemical Information

Publications (6)

Solvente y solubilidad

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

Creatinine Related Classifications

HY-B0504 Related Classifications